A Multi-Center, Inpatient and Ambulatory, Phase 2, Doubleblind, Randomised, Placebo-Controlled Proof of Concept Study of CYR-101 in Patients With DSM-IV Schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2012
At a glance
- Drugs MIN 101 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Sponsors Cyrenaic Pharmaceuticals
- 01 Dec 2010 Status changed from active, no longer recruiting to completed.
- 01 Dec 2010 Results have been reported in a Cyrenaic Pharmaceuticals media release.
- 23 Mar 2009 New trial record
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History